Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
NCT ID | NCT05812807 |
Title | Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab |
Recruitment | Recruiting |
Gender | both |
Phase | Phase III |
Variant Requirements | No |
Sponsors | Alliance for Clinical Trials in Oncology |
Indications | |
Therapies | |
Age Groups: | senior | adult |
Covered Countries | USA | CAN |